← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Revenue increased 87.3% to $616.3M, while Net income increased 1812.4% to $447.2M.
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $616.3MOK
- Profitability — Net income $447.2MOK
- Cash generation — Free cash flow ($25.0M)Note
- Accounting — Formula distress score · manipulation flag raised · earnings quality greyWatch
- Insiders — 0 buys; 2 sells in 365 daysNote
- Capital — Comparable payout data unavailableNote
Business
TG THERAPEUTICS, INC.: Food and Drug Administration (FDA) or any comparable regulatory authority outside of the U.S. for a product candidate and do not achieve broad market acceptance among physicians, patients, healthcare payors, and the medical community, the revenues that we generate from product sales will be limited.
Where the revenue comes from
Fiscal 2025, as TG THERAPEUTICS, INC. reports it. History and quarterly detail are in the app.
- Product$606.9M
- License$9.4M
- Royalty$5.6M
- Other Revenue$3.6M
- License Revenue$152K
Latest filings
- 10-Q · Quarterly report2026-08-05
- 8-K · Company announcement2026-08-03
- 8-K · Company announcement2026-06-12
- 8-K · Company announcement2026-06-03
- 8-K · Company announcement2026-05-27
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about TG THERAPEUTICS, INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.